Effects of Oral Probiotic Product on Vaginal Microbial Community and Parameters of Vaginal Health

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-23

Study Completion Date

2021-03-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess the efficacy and safety of an oral probiotic product on the vaginal microbiome and on parameters of vaginal health. Eligible subjects will utilize the investigational product as directed for a period of 28 days. The vaginal microbial community and parameters of vaginal health will be measured at baseline and after 14 and 28 days of supplementation. A follow-up post-supplementation visit will be conducted on Day 42.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Ameliorative Effects of Oral Probiotics on Bacterial Vaginosis

NCT03116789

Bacterial Vaginosis

COMPLETED NA

Effect of Oral Probiotic Yeast on the Composition of the Vaginal Microbiota in Healthy Women

NCT03574844

Vaginal Health

COMPLETED NA

Probiotic Modulates Vaginal Microflora

NCT05302687

Microbial Colonization

COMPLETED PHASE2/PHASE3

Microbiome Vaginae After Use of Oral Probiotics in Pregnancy.

NCT04778722

Pregnancy; Infection Genitourinary System

UNKNOWN NA

The Influence of Oral Probiotic on the Vaginal Flora and Microenvironment Alteration in the Vaginosis Infection Women

NCT06001190

Probiotic, Human Papillomavirus Infection, Pap Smear, Microbiome

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral probiotic product

Group Type EXPERIMENTAL

Oral probiotic product

Intervention Type DIETARY_SUPPLEMENT

Once per day (QD), 28 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral probiotic product

Once per day (QD), 28 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy women aged 18-50 years.
2. Body mass index 18.5 - 34.9 kg/m2 (inclusive).
3. Have childbearing potential \[i.e. not surgically sterile or post-menopausal (greater than one year since last menses)\].
4. Non-smoker, or ex-smoker ≥6 months.
5. Nugent score of 4-6 or pH \>4.5
6. Agrees to maintain current level of physical activity and dietary habits throughout the trial period.
7. Agrees to discontinue use of probiotic supplements (oral or vaginal), as well as food supplemented with probiotics or prebiotics.
8. Willing and able to provide written informed consent.
9. Agrees to provide fecal samples during the trial period.

Exclusion Criteria

1. Hypersensitivity to any ingredient in the study product.
2. Pregnancy or planning pregnancy.
3. Lactation or breast feeding.
4. Irregular menstrual cycles.
5. Use of contraceptives that contain spermicidal agents.
6. Use of an intrauterine device (IUD).
7. Use of hormonal therapy through cervical cap.
8. Use of douching devices.
9. Any major trauma or surgical event within the 3 months prior to screening.
10. Individuals undergoing therapies to prevent any recurrent infections.
11. Allergy to any antibiotic that may be prescribed as a rescue remedy during the study.
12. Use of prescription drugs (other than birth control) within 1 month prior to Visit 1.
13. Use of antibiotics within 2 months prior to Visit 1.
14. History of blood clotting disorders or use of coagulation-inhibiting drugs (e.g. warfarin)
15. Presence of systemic diseases or immunodeficiencies
16. Abdominal or gastrointestinal surgery within the previous 12 months.
17. Recent gastrointestinal food-borne illness (within 1 month prior to Visit 1)
18. History of cancer (excluding non-melanoma skin cancer and basal cell carcinoma) in the past 5 years
19. Abnormal laboratory test results of clinical significance
20. Presence or history (past 6 months) of alcohol or drug abuse
21. Subject is unwilling or unable to abide by the requirements of the protocol
22. Any condition that would interfere with the subject's ability to comply with study instructions, might confound the interpretation of the study, or put the subject at risk
23. Subject has taken an investigational health product or has participated in a research study within 30 days prior to first study visit

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes